The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors.
 
David H Aggen
Consulting or Advisory Role - Alphasights; Aptitude Health; Astellas Pharma; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Guidepoint Global Advisors; MJH Life Sciences; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Meredith McKean
Consulting or Advisory Role - Castle Biosciences (Inst); IQVIA (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst)
Research Funding - AADi (Inst); Alpine Immune Sciences (Inst); Arcus Biosciences (Inst); Arvinas (Inst); Ascentage Pharma Group (Inst); ASCO (Inst); Astellas Pharma (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioMed Valley Discoveries (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); C4 Therapeutics (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Foghorn Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); Immvira (Inst); Infinity Pharmaceuticals (Inst); Jacobio (Inst); Kechow Pharma (Inst); Kezar Life Sciences (Inst); Kinnate Biopharma (Inst); MedImmune (Inst); Mereo BioPharma (Inst); Metabomed (Inst); Moderna Therapeutics (Inst); NBE Therapeutics (Inst); Nektar (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Oncorus (Inst); OnKure (Inst); PACT Pharma (Inst); Pfizer (Inst); Plexxikon (Inst); Poseida (Inst); Prelude Therapeutics (Inst); Pyramid Biosciences (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Scholar Rock (Inst); Seagen (Inst); Synthorx (Inst); Tempest Therapeutics (Inst); TeneoBio (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Top Alliance BioScience (Inst); Xilio Therapeutics (Inst)
 
Jean H. Hoffman-Censits
Honoraria - Clovis Oncology; Gilead Sciences; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Gilead Sciences; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); EMD Serono (Inst); Foundation Medicine; Genentech; Genentech; Sanofi
Travel, Accommodations, Expenses - Roche/Genentech
 
Nehal J. Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
Omar Alhalabi
Consulting or Advisory Role - Cardinal Health; Seagen; Silverback Therapeutics
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Ikena Oncology (Inst)
 
Elizabeth A. Guancial
Honoraria - Research to Practice
 
Babar Bashir
Consulting or Advisory Role - Merck/Eisai
Research Funding - Amgen (Inst); Artios (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Elucida Oncology (Inst); Gritstone Bio (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); KAHR Medical (Inst); Lyell Immunopharma (Inst); Merck (Inst); Pionyr (Inst); RasCal (Inst); Syros Pharmaceuticals (Inst); Tarveda Therapeutics (Inst)
 
I. Alex Bowman
Consulting or Advisory Role - AstraZeneca; AVEO
Speakers' Bureau - Caris Life Sciences; Natera
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; Fusion Pharmaceuticals; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera; RAPT Therapeutics
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera; Seagen
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera
 
Trupti Lingaraj
Employment - Ikena Oncology; Korro Bio (I)
Stock and Other Ownership Interests - Ikena Oncology; Korro Bio (I)
 
Katherine Kim
Employment - Ikena Oncology
Stock and Other Ownership Interests - Ikena Oncology
 
Marissa Timothy
Employment - Ikena Oncology
 
Nerymar Ortiz-Otero
Employment - Ikena Oncology
Stock and Other Ownership Interests - Ikena Oncology
 
Wilmin Bartolini
Employment - Ikena Oncology
Stock and Other Ownership Interests - Cyclerion; Ikena Oncology; Ironwood Pharmaceuticals; Novartis; Sandoz
 
Katherine Kacena
Consulting or Advisory Role - Ikena Oncology
 
Sergio Santillana
Employment - ARIAD; Ikena Oncology; Merrimack; SLSS Consulting LLC
Leadership - ARIAD; Ikena Oncology; Merrimack; SLSS Consulting LLC
Stock and Other Ownership Interests - Akamara Therapeutics; ARIAD; Ikena Oncology; Merrimack
Consulting or Advisory Role - Akamara Therapeutics; Clarus Ventures; Ikena Oncology; Kyn Therapeutics; Northern Biologics; Partners Therapeutics; YourEncore; Yumanity Therapeutics
Patents, Royalties, Other Intellectual Property - Patent related to work in Takeda (2015-2016) submitted for approval; Work-related patents with Ikena Oncology Inc (2020 to ongoing )
Travel, Accommodations, Expenses - Akamara Therapeutics; ARIAD; Ikena Oncology; Merrimack
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; NeoTX; NeoTX; Onc.AI; Pyxis; STipe Therapeutics; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alnylam; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Codiak Biosciences; Crown Bioscience; CStone Pharmaceuticals; Day One Therapeutics; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; Hotspot Therapeutics; Immunocore; Incyte; Inzen Therapeutics; Janssen; Kadmon; KSQ Therapeutics; Merck; Nektar; Novartis; Onc.AI; Partner Therapeutics; Pfizer; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; SERVIER; Silicon Therapeutics; STINGthera; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics; Tesaro; TRex Bio; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Array BioPharma (Inst); Astellas Pharma (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Fstar (Inst); Genmab (Inst); Ikena Oncology (Inst); Immatics (Inst); Incyte (Inst); Kadmon (Inst); KAHR Medical (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nektar (Inst); NextCure (Inst); Numab (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Scholar Rock (Inst); Spring bank (Inst); Synlogic (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst); Trishula Therapeutics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics